The Relationship Between Vascular Adhesion Protein-1 and Diabetic Cardiovascular Autonomic Neuropathy
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Exploring the relationship between serum VAP-1 and cardiovascular autonomic neuropathy in subjects with type 2 diabetes mellitus
| Condition |
|---|
|
Neuropathy; Peripheral, Autonomic, in Diabetes Mellitus (Manifestation) |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | The Relationship Between Vascular Adhesion Protein-1 and Diabetic Cardiovascular Autonomic Neuropathy |
whole blood
| Estimated Enrollment: | 150 |
| Study Start Date: | March 2009 |
| Estimated Study Completion Date: | May 2014 |
| Estimated Primary Completion Date: | May 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| diabetic mellitus screen |
Detailed Description:
The prevalence of diabetes mellitus is increasing recently, especially in the urban area of developing countries. Subjects with diabetes have higher rate of hospitalization and have higher mortality. Diabetes results in various complications including diabetic retinopathy, nephropathy, neuropathy, and cardiovascular complications. Among these, cardiovascular autonomic neuropathy is one of clinical important complication of diabetes. Diabetic subjects with reduced cardiovascular autonomic function have been shown to strongly associate with an increased risk of silent myocardial ischemia and increased mortality. They also have higher risk of sudden death, intraoperative and perioperative cardiovascular instability. Formation of advanced glycation end product (AGE) and oxidative stress are important causes of diabetic neuropathy. Vascular adhesion protein-1 (VAP-1), an adhesion molecule with an activity of semicarbazide-sensitive amine oxidases (SSAO), which can catalyze endogenous amines to produces corresponding aldehydes, H2O2, and ammonia. We have demonstrated that serum VAP-1 is a source of systemic AGE and oxidative stress, and is associated with nephropathy and atherosclerosis. There are reports demonstrating that subjects with diabetic retinopathy or stroke have higher serum VAP-1. To our best knowledge, there is no report regarding the relationship between serum VAP-1 and neuropathy. In present study, we will measure serum VAP-1 and check cardiovascular autonomic function. We will also explore the relationship between serum VAP-1 and cardiovascular autonomic neuropathy in subjects with type 2 diabetes mellitus.
Eligibility| Ages Eligible for Study: | 10 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
type 2 diabetes mellitus
Inclusion Criteria:
- type 2 diabetes mellitus
Exclusion Criteria:
- arrythmia
Contacts and Locations| Contact: Ying-Chuen Lai | 886-02-23123456 ext 63678 | ying.chuen@msa.hinet.net |
| Taiwan | |
| National Taiwan University Hospital | Recruiting |
| Yun Lin, Taiwan | |
| Contact: Ying-Chuen Lai 886-05-5323911 ext 5125 ying.chuen@msa.hinet.net | |
| Principal Investigator: Ying-Chuen Lai | |
| Study Chair: | Hung-Yaun Li | National Taiwan University Hospital |
More Information
No publications provided
| Responsible Party: | National Taiwan University Hospital |
| ClinicalTrials.gov Identifier: | NCT01706289 History of Changes |
| Other Study ID Numbers: | NTUH20090323HRV |
| Study First Received: | October 10, 2012 |
| Last Updated: | October 12, 2012 |
| Health Authority: | Taiwan: Department of Health |
Keywords provided by National Taiwan University Hospital:
|
diabetes cardiovascular autonomic neuropathy VAP 1 |
Additional relevant MeSH terms:
|
Diabetes Mellitus Peripheral Nervous System Diseases Nervous System Diseases Demyelinating Diseases Polyneuropathies Nerve Compression Syndromes Neurologic Manifestations Neurotoxicity Syndromes |
Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Neuromuscular Diseases Signs and Symptoms Poisoning Substance-Related Disorders |
ClinicalTrials.gov processed this record on May 19, 2013